The QWINT programme consists of five open-label Phase III RCTs performed in both insulin-naive (QWINT-1 and -2) and insulin-experienced (QWINT-3 and -4) individuals with type 2 diabetes, and individuals with type 1 diabetes (QWINT-5) [38–42]. This evidence concerns the gene INS and type 2 diabetes mellitus.